Tse David T, Benedetto Pasquale, Dubovy Sander, Schiffman Joyce C, Feuer William J
Department of Ophthalmology, University of Miami-Miller School of Medicine, 900 NW 17th Street, Miami, FL 33136, USA.
Am J Ophthalmol. 2006 Jan;141(1):44-53. doi: 10.1016/j.ajo.2005.08.068.
To determine the effect of intraarterial cytoreductive chemotherapy (IACC) as an adjunct to conventional surgery and radiation therapy for lacrimal gland adenoid cystic carcinoma (ACC).
A retrospective, comparative, interventional case series.
setting: Institutional. patient population: Nine consecutive patients with lacrimal gland ACC were treated with IACC, followed by orbital exenteration and chemoradiotherapy. This case series was compared with a series of seven patients treated by conventional local therapies in the same institution. intervention procedure: Clinical records, imaging studies, histologic sections, and archival specimens from all 16 patients were reviewed. Information analyzed included site of disease, histologic characteristics, extent of disease, incidence of locoregional recurrence or distant metastases, and disease-free survival and overall survival time. main outcome measure: The effect of IACC was assessed by the radiographic and histologic response and survival outcome in comparison to a historical cohort of patients managed by conventional local therapies.
The difference between the carcinoma cause-specific death rate of the study group versus conventional treatment was significant (P = .029, log rank test). The cumulative 5-year carcinoma cause-specific death rate in the IACC treated group was 16.7% compared with 57.1% in the conventional treatment group. The cumulative 5-year recurrence rate in the IACC treated group was 23.8% compared with 71.4% in the conventional treatment group.
The preliminary data suggest that IACC as an integral component of a multimodal treatment strategy is potentially effective in improving local disease control and overall disease-free survival in lacrimal gland adenoid cystic carcinoma.
确定动脉内减瘤化疗(IACC)作为泪腺腺样囊性癌(ACC)传统手术和放射治疗辅助手段的效果。
一项回顾性、对比性、干预性病例系列研究。
背景:机构研究。患者群体:连续9例泪腺ACC患者接受IACC治疗,随后进行眶内容剜除术及放化疗。该病例系列与同一机构中接受传统局部治疗的7例患者系列进行比较。干预程序:回顾了所有16例患者的临床记录、影像学研究、组织学切片和存档标本。分析的信息包括疾病部位、组织学特征、疾病范围、局部区域复发或远处转移的发生率、无病生存期和总生存期。主要结局指标:与采用传统局部治疗的历史队列患者相比,通过影像学和组织学反应以及生存结局评估IACC的效果。
研究组与传统治疗组的癌症特异性死亡率差异有统计学意义(P = .029,对数秩检验)。IACC治疗组的5年累积癌症特异性死亡率为16.7%,而传统治疗组为57.1%。IACC治疗组的5年累积复发率为23.8%,而传统治疗组为71.4%。
初步数据表明,IACC作为多模式治疗策略的一个组成部分,在改善泪腺腺样囊性癌的局部疾病控制和总体无病生存期方面可能有效。